Product Program year 2025 Source: CMS Open Payments

Bijuva

Drug Menopause

NDC 68308-750-00

Open in the dashboard

General payments

$579,678

1,215 payments

Research payments

$0

0 payments

Through program year 2025, $579,678 in general payments and $0 in research payments were reported against Bijuva (Menopause).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2025 General $579,678 1,215

Breakdown

Who paid General payments · program year 2025
  1. Mayne Pharma Inc. $579,678 1,215 payments
Top recipients General payments · program year 2025
  1. Risa Kagan Obstetrics & Gynecology · Berkeley, CA $50,273 9% · 42 payments
  2. James Simon Gynecology · Washington, DC $45,133 8% · 33 payments
  3. Elliot Cazes Obstetrics & Gynecology · Tampa, FL $41,343 7% · 39 payments
  4. Sharon Winer Reproductive Endocrinology · Beverly Hills, CA $40,514 7% · 32 payments
  5. Lisa Larkin Internal Medicine · Cincinnati, OH $34,819 6% · 25 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Obstetrics & Gynecology $325,084 56% · 248 practitioners
  2. Gynecology Obstetrics & Gynecology $98,666 17% · 25 practitioners
  3. Internal Medicine $40,861 7% · 22 practitioners
  4. Reproductive Endocrinology Obstetrics & Gynecology $40,778 7% · 4 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $20,412 4% · 120 practitioners

The top 5 of 34 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Florida $126,385 22% · 74 recipients
  2. California $112,485 19% · 181 recipients
  3. Texas $57,271 10% · 53 recipients
  4. District of Columbia $45,133 8% · 1 recipient
  5. Ohio $37,717 7% · 28 recipients

The top 5 of 37 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

274

Prescriptions dispensed, refills included

Drug cost

$75,173

Paid at the pharmacy, in all

Prescribers

19

With 11 or more claims of it

Medicare Part D drugs matched to BIJUVA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Bijuva Estradiol/Progesterone Same name 19 274 $75,173

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 19 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Brooke Faught Nurse Practitioner TN 30 $12,243 None on record
Lisa Cheek Nurse Practitioner KY 26 $6,355 None on record
Howard Mandel Obstetrics & Gynecology CA 22 $7,385 None on record
Stephanie Howard Physician Assistant TN 16 $4,789 None on record
Elliot Cazes Obstetrics & Gynecology FL 15 $3,919 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 19 in the dashboard with a free account
1,215 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record